AI-ACCELERATED DRUG DISCOVERY

17-beta-hydroxysteroid dehydrogenase 14

Explore its Potential with AI-Driven Innovation
Predicted by Alphafold

17-beta-hydroxysteroid dehydrogenase 14 - Focused Library Design

Available from Reaxense

This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of 17-beta-hydroxysteroid dehydrogenase 14 including:

1. LLM-powered literature research

Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into 17-beta-hydroxysteroid dehydrogenase 14 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.

 Fig. 1. Preliminary target research workflow

2. AI-Driven Conformational Ensemble Generation

Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of 17-beta-hydroxysteroid dehydrogenase 14, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.

 Fig. 2. AI-powered molecular dynamics simulations workflow

3. Binding pockets identification and characterization

We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.

 Fig. 3. AI-based binding pocket detection workflow

4. AI-Powered Virtual Screening

Our ecosystem is equipped to perform AI-driven virtual screening on 17-beta-hydroxysteroid dehydrogenase 14. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of 17-beta-hydroxysteroid dehydrogenase 14. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.

 Fig. 4. The screening workflow of Receptor.AI

Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.

The focused library for 17-beta-hydroxysteroid dehydrogenase 14 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

17-beta-hydroxysteroid dehydrogenase 14

partner:

Reaxense

upacc:

Q9BPX1

UPID:

DHB14_HUMAN

Alternative names:

17-beta-hydroxysteroid dehydrogenase DHRS10; Dehydrogenase/reductase SDR family member 10; Retinal short-chain dehydrogenase/reductase retSDR3; Short chain dehydrogenase/reductase family 47C member 1

Alternative UPACC:

Q9BPX1; Q9UKU3

Background:

17-beta-hydroxysteroid dehydrogenase 14, also known as DHRS10, plays a crucial role in steroid metabolism by converting oestradiol to oestrone. This enzyme, part of the short chain dehydrogenase/reductase family, exhibits NAD-dependent activity, highlighting its importance in biochemical pathways. Alternative names include Dehydrogenase/reductase SDR family member 10 and Retinal short-chain dehydrogenase/reductase retSDR3.

Therapeutic significance:

Understanding the role of 17-beta-hydroxysteroid dehydrogenase 14 could open doors to potential therapeutic strategies. Its involvement in steroid metabolism makes it a compelling target for drug discovery, aiming to modulate hormonal balances in diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.